Kane Biotech Inc. (KNE.V), on Thursday, announced a non-brokered private placement offering of up to 16 million common shares, priced at $0.05 per share for gross proceeds of up to $800,000.
The financing is intended to support working capital and general corporate purposes, with closing expected on or about December 17, 2025. Certain insiders of Kane Biotech may participate in the offering, reflecting confidence in the company's strategy. All shares issued will carry a four-month-plus-one-day hold period, in line with TSX Venture Exchange requirements.
The transaction positions Kane Biotech to continue advancing its Revyve wound care portfolio, which targets microbial biofilms —a major contributor to antibiotic resistance and poor healing outcomes.
The company's Revyve Antimicrobial Wound Gel and Gel Spray are FDA 510(k) cleared in the United States and approved by Health Canada, offering novel solutions for chronic wound management. The company's Revyve Antimicrobial Wound Cleanser, was submitted for FDA 510(k) clearance in September 2025, and approval remains pending.
The stock ended Wednesday's session at $0.035. Over the past 12 months KNE.V has traded in the range of $0.030 to $0.130.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.